Arrowhead Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines that treat diseases with a genetic basis, typically characterized by the overproduction of specific proteins. The company's core technology is its Targeted RNAi Molecule (TRiM) platform, which enables the delivery of RNA therapeutics to various cell types to induce rapid and durable knockdown of target genes. Arrowhead's pipeline includes numerous clinical-stage candidates targeting cardiometabolic, pulmonary, liver, and central nervous system disorders. In 2025, the company transitioned to a commercial-stage entity with the FDA approval of REDEMPLO (plozasiran) for adults with familial chylomicronemia syndrome. Arrowhead also maintains strategic licensing and collaboration agreements with major pharmaceutical companies, including Novartis, GSK, Amgen, Takeda, and Sarepta Therapeutics, to advance and commercialize select programs globally.
